CompletedNCT02636842

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.

Medication studyAges 18–65United States

The study in practice

Understand this study

This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Cerritos and 5 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateDecember 2015

Recruitment status: Completed
Enrollment listed in the registry: 47
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT02636842
Official title: Show the full official title
A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder

Completed

Cerritos · Lemon Grove · Oakland

3 more locations

FAQ

What did researchers investigate?

This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole Lauroxil.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.